Luminescence experiments involved in the mechanism of streptozotocin diabetes and cataract formation.
Streptozotocin (STZ)-induced diabetes is linked to excessive nitric oxide (NO), and possibly peroxynitrite (OONO(-)) and/or other nitrogen oxides, e.g. nitrogen trioxide (N(2)O(3)), which damages DNA of pancreatic beta cells, causing death and loss of insulin. Simultaneous injection of carboxy-PTIO (CPTIO) and STZ prevents diabetes and cataract formation in rats, whereas 4-hydroxy-Tempo (4HT) does not. CPTIO oxidizes nitric oxide to nitrite, which prevents production of the diabetogenic toxin. Peroxynitrite may not be involved, since 4HT (converts O(2)(-) to H(2)O(2)) injected with STZ produces diabetes. All six of the control rats injected with STZ became diabetic and developed cataracts after 3 months. Eight rats injected with STZ and CPTIO were non-diabetic with no cataracts up to a year. This work establishes the idea that excessive nitric oxide is a primary initiator in STZ diabetes. Luminescence experiments using OONO(-) generation from SIN-1 with L-012 indicates that 4HT is an effective inhibitor, while CPTIO is ineffective. Experiments with dilute solutions of nitrogen trioxide added to ladder or plasmid DNA reveal extensive nicking of DNA, thereby raising the possibility that other oxides of nitrogen could be involved with the damage to DNA. It can be concluded that diabetes can be prevented by oxidizing excessive NO from STZ.
Van Dyke
Knox
K
Department of Biochemistry and Molecular Pharmacology, Robert C. Byrd Medical Center, West Virginia University, Morgantown, WV 26506, USA. kvandyke@hsc.wvu.edu
Ghareeb
Erica
E
Van Dyke
Mark
M
Sosa
Arturo
A
Hoeldtke
Robert D
RD
Van Thiel
David H
DH
D000818:Animals; D001565:Benzoates / Q000494:pharmacology*; D002386:Cataract / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control*; D003497:Cyclic N-Oxides / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D019811:Hydroxylamine / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology*; D049449:Luminescence; D008163:Luminescent Measurements; D008165:Luminol / Q000031:analogs & derivatives / Q000737:chemistry; D008297:Male; D008981:Molsidomine / Q000031:analogs & derivatives* / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism; D010084:Oxidation-Reduction; D030421:Peroxynitrous Acid / Q000737:chemistry; D051381:Rats; D017207:Rats, Sprague-Dawley; D013311:Streptozocin / Q000494:pharmacology*; D013997:Time Factors
D001565:Benzoates; D003497:Cyclic N-Oxides; D004791:Enzyme Inhibitors; D007093:Imidazoles; C081614:L 012; C079393:1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole; D030421:Peroxynitrous Acid; D019811:Hydroxylamine; D009569:Nitric Oxide; D008165:Luminol; C002385:linsidomine; D013311:Streptozocin; D008981:Molsidomine; C505333:TEMPOL-H